2021 Attendee Profile

2021 reached record attendance with over 290 registrants!

2020 Event Features:

OPT Congress 2020 Features:

The Oligonucleotide & Precision Therapeutics Congress 2020 brought record attendance last year, with over 250+ professionals from the oligonucleotide discovery and development field. With 2 expanded conferences, poster viewing sessions, an educational short course, exhibit hall and networking opportunities, and several breakout discussions, the event proved that we can still connect and engage the same way we do at in-person events. We hope you will join us in March 2021.

2019 Attendee Profile

OPT Congress 2019
Attended by more than 130 unique companies

The Fourth Annual “Oligonucleotide & Precision Therapeutics” (OPT Congress) was held March 26-28, 2019 at the Hyatt Regency Cambridge, in Cambridge, Massachusetts.

More than 200 industry leaders from 14 different countries joined the 2-day program dedicated to Oligonucleotide Discovery & Delivery, CMC and Regulatory Strategies. In addition, we delivered two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair. NEW for 2020 we will be assessing the impact of AI on drug discovery.

The congress participation was represented well with 55% attended by executives. With more than 65% of the audience from biotech, another 15% from pharma, and the event represented by 130+ unique organizations, this event will continue to gather a diverse body of attendees from around the world to network, share ideas, and discuss cutting-edge science and technology.

2019 Event Features

• 200+ Participants
• 2 Conferences
• 2 Symposium
• Dinner Courses
• Dedicated Poster Viewing Sessions
• Dedicated Exhibit Hall Hours and Networking Functions
  

Hear what a few people had to say about OPT Congress 2019

“Well balanced content, perfectly executed logistics.”
     Dmitry S., PhD, CTO, Sirnaomics

“The scientific quality of the presentations was very high and the opportunities for networking were excellent.”
Ekkehard L., PhD, Senior Director, R&D Alliance Management, Sanofi

With special thanks to our Executive Advisory Board who help to shape the program:

• Arthur Levin, PhD, Executive Vice President, Research and Development, Avidity Biosciences
• Muthiah (Mano) Manoharan, PhD, Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals
• Dmitry Samarsky, PhD, CTO, Sirnaomics
• Lubo Nechev, PhD, Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

RNA Targeting with Antisense Oligonucleotides: Present and Future
Geary_RichardRichard S. Geary, PhD, Senior Vice President, Development, Ionis Pharmaceuticals

Key Contacts